Presbyopia Market: Epidemiology, Therapies, and Key Companies Working in the Market | AbbVie, Eyenovia, Orasis Pharmaceuticals, Novartis, Visus Therapeutics, LENZ Therapeutics, Glaukos Corporation, Ocuphire Pharma

DelveInsight's 'Presbyopia - Market Insights, Epidemiology, and Market Forecast-2034' report deliver an in-depth understanding of Presbyopia, historical and forecasted epidemiology as well as Presbyopia market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
DelveInsight has launched a new report on "Presbyopia - Market Insights, Epidemiology, and Market Forecast-2034". Visit: https://www.delveinsight.com/report-store/presbyopia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Presbyopia Market Report:
In 2023, the therapeutic market for presbyopia across the 7MM was approximately USD 17 billion. The United States held the largest share, accounting for around 48% of this total market, significantly surpassing other major markets including the EU4 countries (Germany, France, Italy, Spain), the United Kingdom, and Japan.
Among European countries, Germany led with the highest market size, reaching nearly USD 1.666 billion in 2023, while Spain had the smallest market size at approximately USD 938 million. In Japan, the market for presbyopia was estimated at around USD 2.642 billion in 2023, representing 16% of the overall market across the 7MM.
With the anticipated introduction of new therapies such as LNZ100 (Aceclidine), significant changes in the market size for presbyopia are expected in the coming years.
According to estimates from DelveInsight, there were approximately 278 million diagnosed cases of presbyopia across the 7MM in 2023, with this number expected to rise by 2034. The US had the largest market for presbyopia in 2023, valued at around USD 8,039 million, and this market is projected to grow further by 2034.
Currently, VUITY is a key treatment for presbyopia, with a market size of approximately USD 257 million in the 7MM in 2023. Presbyopia treatments primarily involve pharmacological therapies such as parasympathomimetics or cholinomimetics.
Emerging therapies like Phentolamine Ophthalmic Solution 0.75% (PS) are expected to impact the market significantly. Phentolamine is anticipated to be available in the US by 2025, in the EU4 and the UK by 2026, and in Japan by 2027, potentially alleviating the presbyopia burden in the coming years.
Know more about presbyopia interesting facts @ https://www.delveinsight.com/report-store/presbyopia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Presbyopia Market Report:
• Presbyopia market report covers a descriptive overview and comprehensive insight of the Presbyopia Epidemiology and Presbyopia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
• The Presbyopia market report provides insights on the current and emerging therapies.
• Presbyopia market report provides a global historical and forecasted market covering drug outreach in 7MM.
• The Presbyopia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Presbyopia market.
Got queries? Click here to know more about the Presbyopia Market Landscape @ https://www.delveinsight.com/sample-request/presbyopia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Presbyopia Overview
Presbyopia is a common age-related condition characterized by a gradual loss of near vision, typically becoming noticeable after age 40 and progressing between ages 40 and 60. This decline in near vision is due to the natural aging process, which causes the eye's lenses to lose elasticity. Over time, the proteins in the lens change, leading to thickening, hardening, and reduced flexibility. These changes impair the lens's ability to refract light correctly, diminishing the eye's focusing capacity. Presbyopia can be classified into several types, including incipient, functional, absolute, premature, and nocturnal presbyopia. Although aging is the primary risk factor, presbyopia can also develop prematurely due to factors such as trauma, systemic diseases, cardiovascular conditions, or medication side effects. Early symptoms include difficulty with prolonged close-up tasks, eye strain that worsens in low light, delays in focusing at various distances, ocular discomfort, headaches, asthenopia, squinting, fatigue from near work, increased working distance, a need for brighter lighting when reading, and diplopia. Recognizing these symptoms and understanding their underlying mechanisms are essential for effective management and treatment.

Diagnosis of presbyopia involves a thorough eye examination by an ophthalmologist, including evaluations of the retina, muscle function, refraction, slit-lamp assessment, visual field, and visual acuity. An ophthalmoscope is used to inspect the retina, optic disk, and choroid. Muscle function is assessed by having the patient follow a moving object. Refractive tests measure how light bends through the cornea and lens to determine the correct prescription. A slit-lamp exam provides a detailed view of the eye's anterior structures, while visual field tests measure peripheral vision and visual acuity tests assess clarity at different distances. Pupil-dilating drops may be used to temporarily increase light sensitivity. These comprehensive evaluations ensure accurate diagnosis and overall ocular health.

Treatment for presbyopia aims to address the eye's reduced ability to focus on nearby objects and includes several options based on the patient's needs. Optical correction can be achieved with corrective eyeglasses or contact lenses. For those seeking more permanent solutions, refractive surgery or lens implants are available. Refractive surgical options include Conductive Keratoplasty, LASIK, LASEK, and Photorefractive Keratectomy, which have become safer and more effective with technological advances. Additionally, current management may involve off-label use of nonsteroidal anti-inflammatory drugs (NSAIDs), parasympathetic agonists, miotic agents, and other treatments. Commonly used agents include Pilocarpine, Carbachol, Aceclidine, Brimonidine, and Nepafenac. Each treatment is tailored to the patient's specific needs, offering a comprehensive approach to managing presbyopia.

Despite available treatments, presbyopia affects a large portion of the aging population, and many current options are costly and inaccessible. Advanced surgical procedures are often prohibitively expensive and not typically covered by insurance, posing a barrier for many individuals. There is a pressing need for affordable, non-invasive solutions that accommodate diverse socioeconomic backgrounds.

Topical agents like pilocarpine drops, including the innovative VUITY, represent progress but fall short of expectations. With a daily cost of about USD 3 for a 30-day supply and lack of insurance coverage, these treatments are impractical for many. Real-world feedback and AbbVie's reduced marketing efforts highlight the need for more effective treatments with fewer applications and longer-lasting effects. Addressing these issues is crucial for improving the quality of life for those affected by presbyopia.
Presbyopia Epidemiology Insights:
In the assessment conducted by DelveInsight, the total prevalent cases of presbyopia in the 7 major markets (7MM) were estimated to be approximately 325 million in 2023. The United States had the highest total diagnosed prevalent cases of presbyopia, with nearly 109 million cases, and this number is anticipated to increase in the future. Among European countries, Germany reported the highest diagnosed prevalent cases of presbyopia, with approximately 32 million cases, followed by Italy with about 24 million cases. Spain had the lowest diagnosed prevalent population, with around 18 million cases. Japan accounted for approximately 50 million total diagnosed prevalent cases of presbyopia in 2023, representing about 18% of the total in the 7MM.
In the US, the gender-specific diagnosed prevalent cases of presbyopia were highest among females, comprising approximately 60%, compared to males at approximately 40%. This difference is attributed to factors such as hormonal differences, ocular anatomy and physiology, lifestyle, and occupational factors. The age-specific instances of presbyopia in the 7MM were highest for the age group 60-69, with approximately 78 million cases, followed by the age group under 60 years, 70-79 years, and 80 years and above, with approximately 77 million, 69 million, and 53 million cases, respectively, in 2023.
In 2023, presbyopia cases were further categorized based on severity into mild and moderate to severe. Among the 7MM, the highest diagnosed prevalence was observed in moderate to severe cases, with approximately 212 million cases, compared to about 56 million mild cases.
Download our detailed report @ https://www.delveinsight.com/sample-request/presbyopia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Presbyopia Market Outlook
The market for presbyopia treatments features a broad array of options to meet diverse patient preferences and needs. Non-invasive solutions like reading glasses, bifocals, and progressive lenses provide clear vision at various distances, making them popular choices for those seeking convenience. Contact lenses, including multifocal and monovision types, offer enhanced flexibility and a broader field of vision compared to traditional eyewear.

Pharmacological treatments have also shown promise. Eye drops such as pilocarpine hydrochloride temporarily improve near vision by constricting the pupil, thus enhancing the depth of field. Notable advancements include FDA-approved treatments like VUITY and QLOSI, which mark significant progress in managing presbyopia.

Despite these advancements, the market for presbyopia treatments continues to evolve. The current FDA-approved therapies are limited, revealing a substantial gap in available options. This gap presents opportunities for innovation and development, as there remains a considerable demand for new, effective treatments to meet the varied needs of individuals with presbyopia.

Looking ahead, numerous companies, including Visus Therapeutics and others, are exploring new agents for presbyopia. Many pharmaceutical firms are actively conducting clinical trials to develop novel therapies for this condition, indicating a vibrant and evolving treatment landscape.
Presbyopia Marketed Drugs
VUITY (pilocarpine HCI ophthalmic solution) 1.25%: Allergan/AbbVie
QLOSI (pilocarpine hydrochloride ophthalmic solution) 0.4%: Orasis Pharmaceuticals
Presbyopia Emerging Drugs
Brimochol PF (VT-1011): Visus Therapeutics
LNZ100 - 1.75% Aceclidine: LENZ Therapeutics, Inc.
Presbyopia Pipeline Therapies and Key Companies
• AGN-190584: Allergan (acquired by AbbVie)
• MicroLine (Pilocarpine Ophthalmic): Eyenovia
• PresbiDrops (CSF-1): Orasis Pharmaceuticals
• UNR844 (Lipoic acid choline ester): Novartis
• Nyxol (Phentolamine Mesylate): Ocuphire Pharma
• VTI-001 (Brimochol): Visus Therapeutics
• AGN-241622: Allergan (acquired by AbbVie)
Know more about the companies and therapies in the presbyopia market @ https://www.delveinsight.com/report-store/presbyopia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Presbyopia Market Drivers
• Increase in geriatric population
• Increasing research in pharmaceutical treatment
• An upsurge in launch of products
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Presbyopia Patient Share (%) Overview at a Glance
5. Presbyopia Market Overview at a Glance
6. Presbyopia Disease Background and Overview
7. Presbyopia Epidemiology and Patient Population
8. Country-Specific Patient Population of Presbyopia
9. Presbyopia Current Treatment and Medical Practices
10. Unmet Needs
11. Presbyopia Emerging Therapies
12. Presbyopia Market Outlook
13. Country-Wise Presbyopia Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Presbyopia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Trending Reports By DelveInsight:

Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market

Lebers Hereditary Optic Neuropathy Lhon Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market

Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market

Hypoplastic Left Heart Syndrome Hlhs Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market

Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome CIS Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market

Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market

Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market

Media Contact
Kritika Rehani
krehani@delveinsight.com
+14699457679

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.